Ultrasound Technology to Overcome the Blood-Brain Barrier (BBB)

The brain tissue has been severely limited in drug delivery due to the blood-brain barrier (BBB), which blocks harmful substances. SonoCloud-9, an implantable low-intensity focused ultrasound (LIPUS) device developed by CarThera, a French company, temporarily opens the blood-brain barrier (BBB) when combined with microbubbles, increasing drug permeability. This is garnering significant attention in the medical community as it provides a new treatment pathway for patients with recurrent glioblastoma (rGBM), who have previously lacked effective treatment options. The device's mechanism of action, which opens the blood-brain barrier (BBB) for approximately four hours through ultrasound, can be considered an innovative approach that overcomes the limitations of existing chemotherapy.

Maximizing the Delivery Efficiency of Carboplatin

Carboplatin, a chemotherapeutic agent, has an excellent mechanism of action that inhibits the proliferation of cancer cells by cross-linking DNA strands, but it has been difficult to use in the treatment of glioblastoma because it cannot cross the blood-brain barrier (BBB). However, when used in combination with SonoCloud-9, clinical trials in Phase 1/2 have confirmed that the concentration of carboplatin reaching the brain tissue is significantly higher than before. This approach, which physically improves the drug's in vivo mechanism, is economically viable as it maximizes the efficacy of existing, proven anticancer drugs instead of investing huge costs in developing new drugs. The strategy aims to increase drug bioavailability and improve both objective response rate (ORR) and overall survival.

Validation of Superiority Compared to Standard Therapy and Regulatory Benefits

The ongoing Phase 3 clinical trial, SONOBIRD, compares a group of patients with recurrent glioblastoma who receive standard chemotherapy, either lomustine (CCNU) or temozolomide (TMZ) alone, with a group that receives SonoCloud-9 in combination with carboplatin. The U.S. Food and Drug Administration (FDA) recognized the therapeutic value of this technology and granted SonoCloud-9 the Breakthrough Device Designation in June 2022. Close collaboration with regulatory agencies is expected to expedite the approval review process, significantly shortening the timeline for commercialization. The primary endpoint is to improve the overall survival (OS) of patients, with a focus on demonstrating treatment efficacy.

Securing Financial Stability and Expanding into the Brain Disease Market

CarThera completed a Series B funding round of €42 million (approximately $45 million) by December 2023, securing the necessary funds to conduct the Phase 3 clinical trial. With the global glioblastoma (GBM) treatment market estimated at up to $4 billion by 2025-2026, this technology has the potential to reshape the standard of care if approved. Furthermore, the blood-brain barrier (BBB) opening technology can be expanded as a platform for delivering various drugs to other brain diseases such as Alzheimer's disease and Parkinson's disease, making it a highly valuable long-term investment. As a drug delivery platform technology, it can set a standard for a combination product business model that encompasses both the device and pharmaceutical markets.